Fig. 2

Bar chart showing various ADR the participants believe should be reported (n = 450). 96.2% of the respondents believe that reactions to newly introduced drugs to the market need to be reported, while 79.1% believe so for old drugs already in the market. The respondents were favorable to reporting reactions leading to death (96.9%), reactions leading to persistent disability, and reactions leading to hospitalization (97.5%). Just 61.7% believe that minor reactions such as vomiting and diarrhea should be reported